DIANTHUS THERAPEUTICS, INC.

Altre lingue Dianthus Therapeutics, Inc.

Azioni

DNTH

US2528281080

Tempo reale stimato Cboe BZX Altri mercati azionari 16:58:50 27/06/2024			Variaz. 5gg	Var. 1 gen.
25,68 ^USD	+8,40%		-4,78%	+127,79%

16/05	DIANTHUS THERAPEUTICS, INC. : HC Wainwright rimane Buy	ZM
10/05	DIANTHUS THERAPEUTICS, INC. : Wedbush mantiene la raccomandazione Buy	ZM

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy	12/06
Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial	12/06
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)	12/06
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference	30/05
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results	09/05
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference	08/05
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc	11/04
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting	11/04
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results	21/03
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07/03
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)	26/02
Dianthus Therapeutics, Inc. Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis	26/02
Dianthus Therapeutics, Inc. announced that it expects to receive $229.997318 million in funding	22/01
Dianthus Therapeutics, Inc. Announces Executive Appointments	29/11
Dianthus Therapeutics, Inc. announced that it has received $71.987749 million in funding from a group of investors	11/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Assicura e Aumenta la Performance dei tuoi Investimenti con il nostro Team di Esperti al tuo fianco

Assicurare i miei Investimenti

fermer